Mohammad Keykhaei1, Masood Masinaei1,2, Esmaeil Mohammadi1, Sina Azadnajafabad1, Negar Rezaei1,3, Sahar Saeedi Moghaddam1, Nazila Rezaei1, Maryam Nasserinejad1,4, Mohsen Abbasi-Kangevari1,5, Mohammad-Reza Malekpour1, Seyyed-Hadi Ghamari1,5, Rosa Haghshenas1,3, Kamyar Koliji6, Farzad Kompani7, Farshad Farzadfar8,9. 1. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 2. Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran. 3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 4. Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran. 5. Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 6. Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran. 7. Division of Hematology and Oncology, Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran. 8. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. f-farzadfar@tums.ac.ir. 9. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. f-farzadfar@tums.ac.ir.
Abstract
BACKGROUND: Hematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. So far, despite the major epidemiologic concerns about the quality of care, limited data are available for patients with HMs. Thus, we created a novel measure-Quality of Care Index (QCI)-to appraise the quality of care in different populations. METHODS: The Global Burden of Disease data from 1990 to 2017 applied in our study. We performed a principal component analysis on several secondary indices from the major primary indices, including incidence, prevalence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) to create the QCI, which provides an overall score of 0-100 of the quality of cancer care. We estimated the QCI for each age group on different scales and constructed the gender disparity ratio to evaluate the gender disparity of care in HMs. RESULTS: Globally, while the overall age-standardized incidence rate of HMs increased from 1990 to 2017, the age-standardized DALYs and death rates decreased during the same period. Across countries, in 2017, Iceland (100), New Zealand (100), Australia (99.9), and China (99.3) had the highest QCI scores for non-Hodgkin lymphoma, multiple myeloma, Hodgkin lymphoma, and leukemia. Conversely, Central African Republic (11.5 and 6.1), Eritrea (9.6), and Mongolia (5.4) had the lowest QCI scores for the mentioned malignancies respectively. Overall, the QCI score was positively associated with higher sociodemographic of nations, and was negatively associated with age advancing. CONCLUSIONS: The QCI provides a robust metric to evaluate the quality of care that empowers policymakers on their responsibility to allocate the resources effectively. We found that there is an association between development status and QCI and gender equity, indicating that instant policy attention is demanded to improve health-care access.
BACKGROUND:Hematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. So far, despite the major epidemiologic concerns about the quality of care, limited data are available for patients with HMs. Thus, we created a novel measure-Quality of Care Index (QCI)-to appraise the quality of care in different populations. METHODS: The Global Burden of Disease data from 1990 to 2017 applied in our study. We performed a principal component analysis on several secondary indices from the major primary indices, including incidence, prevalence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) to create the QCI, which provides an overall score of 0-100 of the quality of cancer care. We estimated the QCI for each age group on different scales and constructed the gender disparity ratio to evaluate the gender disparity of care in HMs. RESULTS: Globally, while the overall age-standardized incidence rate of HMs increased from 1990 to 2017, the age-standardized DALYs and death rates decreased during the same period. Across countries, in 2017, Iceland (100), New Zealand (100), Australia (99.9), and China (99.3) had the highest QCI scores for non-Hodgkin lymphoma, multiple myeloma, Hodgkin lymphoma, and leukemia. Conversely, Central African Republic (11.5 and 6.1), Eritrea (9.6), and Mongolia (5.4) had the lowest QCI scores for the mentioned malignancies respectively. Overall, the QCI score was positively associated with higher sociodemographic of nations, and was negatively associated with age advancing. CONCLUSIONS: The QCI provides a robust metric to evaluate the quality of care that empowers policymakers on their responsibility to allocate the resources effectively. We found that there is an association between development status and QCI and gender equity, indicating that instant policy attention is demanded to improve health-care access.
Entities:
Keywords:
Hematologic malignancies; Hodgkin lymphoma; Leukemia; Multiple myeloma; Non-hodgkin lymphoma; Quality of Care Index
Authors: Elizabeth Goss; Ana Maria Lopez; Carol L Brown; Dana S Wollins; Otis W Brawley; Derek Raghavan Journal: J Clin Oncol Date: 2009-04-29 Impact factor: 44.544
Authors: Beverly Moy; Blase N Polite; Michael T Halpern; Steven K Stranne; Eric P Winer; Dana S Wollins; Lisa A Newman Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Gretchen A Stevens; Leontine Alkema; Robert E Black; J Ties Boerma; Gary S Collins; Majid Ezzati; John T Grove; Daniel R Hogan; Margaret C Hogan; Richard Horton; Joy E Lawn; Ana Marušić; Colin D Mathers; Christopher J L Murray; Igor Rudan; Joshua A Salomon; Paul J Simpson; Theo Vos; Vivian Welch Journal: Lancet Date: 2016-06-28 Impact factor: 79.321